Palladiem’s AstraZeneca AZN Stock Holding History

Palladiem’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$269K	Hold	1,416	–	–	0.26%	45
2026 Q1	$290K	Buy	1,416 +4	+0.3%	+$771	0.28%	40
2025 Q4	$261K	Buy	+1,412	New	+$248K	0.25%	44
2023 Q3	$279K	Hold	2,058	–	–	0.3%	39
2023 Q2	$295K	Hold	2,058	–	–	0.3%	40
2023 Q1	$286K	Sell	2,058 -10	-0.5%	-$1.34K	0.3%	35
2022 Q4	$280K	Hold	2,068	–	–	0.29%	38
2022 Q3	$227K	Buy	+2,068	New	+$262K	0.24%	42
2015 Q3	$43K	Hold	677	–	–	0.07%	50
2015 Q2	$43K	Hold	677	–	–	0.04%	63
2015 Q1	$46K	Hold	677	–	–	0.04%	70
2014 Q4	$48K	Buy	+677	New	+$48.5K	0.04%	71

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Palladiem's AZN Position: Q2 2026 in Review

Palladiem held its AstraZeneca (AZN) position steady in Q2 2026 at 1,416 shares worth $269K. The position accounts for 0.26% of the portfolio, ranked #45.

Palladiem first reported a position in AZN in Q4 2014 and has held it in 12 quarters since. The position peaked at $295K in Q2 2023. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Palladiem held 1,416 shares of AstraZeneca worth $269K as of Q2 2026.
Palladiem left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.26% of Palladiem's portfolio in Q2 2026, its #45 holding.
Palladiem first reported a position in AstraZeneca in Q4 2014 and has held it in 12 quarters since.
Palladiem's AstraZeneca position peaked at $295K in Q2 2023.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Palladiem's 13F filing for Q2 2026, filed 13 Aug 2026.